Literature DB >> 23224363

Brimonidine-timolol fixed combination induced granulomatous inflammation of the eye.

María Alejandra Carrasco1, Bernardo Ariel Schlaen, Jorge Oscar Zárate.   

Abstract

We report on two cases of granulomatous conjunctivitis and uveitis related with the use of a brimonidine-timolol fixed combination. Case report and a review of medical literature. A 64-year-old man was diagnosed with marked granulomatous uveitis and a 57-year-old woman was diagnosed with granulomatous conjunctivitis. Both patients were using a topical fixed combination of brimonidine 0.2 %-timolol 0.5 % for open angle glaucoma. Bilateral granulomatous uveitis and conjunctivitis were diagnosed after 16 months of treatment with a fixed combination of brimonidine-timolol in both cases. Granulomatous inflammation resolved with the cessation of antiglaucomatous drugs and topical corticosteroid treatment. When the inflammation had resolved completely, both patients were rechallenged with topical brimonidine in one eye only to determine causality. Conjunctival hyperemia is a common side effect of glaucoma medications and is sometimes overlooked. Hyperemia may be associated with other signs such as iritis and keratic precipitates or conjunctival inflammation. In such cases, granulomatous inflammation may be considered in the differential diagnosis. The fixed-combination of brimonidine-timolol may cause this clinical picture.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23224363     DOI: 10.1007/s10792-012-9688-0

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  10 in total

1.  Anterior uveitis as a side effect of topical brimonidine.

Authors:  D B Byles; P Frith; J F Salmon
Journal:  Am J Ophthalmol       Date:  2000-09       Impact factor: 5.258

2.  Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate.

Authors:  Heidi I Becker; R Christopher Walton; Jonathan I Diamant; Michael E Zegans
Journal:  Arch Ophthalmol       Date:  2004-07

3.  Reduced ocular allergy with fixed-combination 0.2% brimonidine-0.5% timolol.

Authors:  Jorge A Alvarado
Journal:  Arch Ophthalmol       Date:  2007-05

4.  Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.

Authors:  S Melamed; R David
Journal:  Clin Ther       Date:  2000-01       Impact factor: 3.393

5.  Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.

Authors:  L Jay Katz
Journal:  J Glaucoma       Date:  2002-04       Impact factor: 2.503

Review 6.  [Drug induced uveitis].

Authors:  J Cano Parra; M Díaz-Llopis
Journal:  Arch Soc Esp Oftalmol       Date:  2005-03

7.  Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.

Authors:  Mark B Sherwood; E Randy Craven; Connie Chou; Harvey B DuBiner; Amy L Batoosingh; Rhett M Schiffman; Scott M Whitcup
Journal:  Arch Ophthalmol       Date:  2006-09

8.  Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy.

Authors:  Michael A Motolko
Journal:  Curr Med Res Opin       Date:  2008-08-07       Impact factor: 2.580

9.  Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.

Authors:  A A Acheampong; M Shackleton; D D Tang-Liu
Journal:  Drug Metab Dispos       Date:  1995-07       Impact factor: 3.922

10.  Brimonidine-induced anterior uveitis and conjunctivitis: clinical and histologic features.

Authors:  Ethan V Nguyen; Domit Azar; Daya Papalkar; Peter McCluskey
Journal:  J Glaucoma       Date:  2008 Jan-Feb       Impact factor: 2.503

  10 in total
  2 in total

1.  Suspected granulomatous anterior uveitis associated with brimonidine tartrate 0.2% and timolol maleate 0.5% ophthalmic solution.

Authors:  Alfonso Casado; Carmen Cabarga; Miguel A de la Fuente; Francisco J Muñoz-Negrete
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-07-09       Impact factor: 3.117

2.  [Iritis : What has glaucoma to do with it?]

Authors:  S Hopf; V Prokosch; C Bornscheuer; N Pfeiffer
Journal:  Ophthalmologe       Date:  2017-01       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.